Close menu




November 9th, 2022 | 13:31 CET

BioNTech, Porsche and Pathfinder Ventures - Looking good

  • Camping
  • RV
  • Biotechnology
Photo credits: pixabay.com

BioNTech's figures were convincing, and the chart looks good again. Porsche is doing well. Not all analysts see further price potential and the price targets diverge. However, a promotion to the DAX beckons. Pathfinder Ventures is also benefiting from surprisingly high demand. The winter camping resort offers are practically sold out. But first to BioNTech. After competitor Moderna had disappointed last week, the quarterly figures of the Mainz-based biotech Company were convincing. And due to the full pipeline, investors can expect a lively news flow in the coming year. Analysts are bullish.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , PORSCHE AG | DE000PAG9113 , PATHFINDER VENTURES INC | CA70323P1071

Table of contents:


    Joe Bleackley, CEO, Pathfinder Ventures Inc.
    "[...] In addition to campsite fees, Pathfinder Ventures has put itself in a position to offer all of these sought-after camping solutions. The only thing they don't sell is the RV itself. [...]" Joe Bleackley, CEO, Pathfinder Ventures Inc.

    Full interview

     

    BioNTech: More than EUR 15 billion in the cash box

    Berenberg continues to recommend BioNTech's stock as a "buy" after the publication of the quarterly figures. The price target remains unchanged at USD 312. Thus, the analysts see almost 100% price potential. They were pleased with the continued high revenues from the sale of the COVID-19 vaccine. These are resilient, they said. Now the focus is on the coming year and the development pipeline. With that, some positive momentum can be expected. Review: BioNTech had sales of about EUR 3.5 billion in the third quarter. Net income was a tidy EUR 1.8 billion, which is more than analysts had expected on average.

    In addition, the Mainz-based biotech Company specified its forecast for the full year 2022 at the upper end. Thus, annual sales are expected to be EUR 16 to 17 billion (previously EUR 13 to 17 billion). At the end of the third quarter, BioNTech already had a bulging treasury. The Company had EUR 13.4 billion in cash and cash equivalents at its disposal. In addition, a large part of the EUR 7.3 billion in trade receivables outstanding at the reporting date had already been received. As a result, the Company is fully financed for the coming years. To put this in perspective: In the current year, the costs for research, sales/administration and capital expenditures will total a maximum of EUR 2.6 billion. That means the Company can continue to go full throttle, particularly in cancer research. The pipeline currently comprises 19 product candidates in 24 ongoing clinical trials. For the coming year, BioNTech expects new data from up to 10 clinical trials.

    Pathfinder Ventures: Cash register rings even in winter

    Pathfinder Ventures is still a long way from billions in sales. Nevertheless, the Canadians have an exciting growth story. The Company is currently building a network of upscale, family-friendly campgrounds and RV parks in western Canada. In this way, it benefits from the trend toward self-directed vacations in the great outdoors. Pathfinder is only at the beginning of its growth and investment phase. Still, the operating result is already profitable at this early stage - especially important in an environment of rising interest rates. There is plenty of growth potential for the coming years. The camping market in Canada alone is worth CAD 2.3 billion - and expansion into the US should not be a major problem.

    Contrary to what may be assumed, the Company also generates revenue in the winter months, with the winter vacation program running since mid-October. Guests stay at Pathfinder Camp Resorts until mid-April. And the offer is in high demand. The booking rate is currently 47%, the Company said. 96% of the locations in the winter vacation program are already fully booked to date. Therefore, capacities are to be increased in the coming winter. "We are extremely pleased with these numbers as we strive for continued growth in all of our resorts for what has been called the 'off-season,'" said Joe Bleackley, Pathfinder's CEO. Pathfinder is thus demonstrating that it is not only growing through acquisitions but also continuing to develop its existing locations.

    Porsche: Price targets diverge significantly

    It has now been 30 days since Porsche's IPO. That means the standstill period for the accompanying banks has ended, and their analysts can now have their say. As a result, there were six new research studies on the sports car pioneer yesterday. Four analysts recommend buying, and two recommend holding. JPMorgan is the most optimistic. The analysts name a target price of EUR 140. The earnings momentum is easy to plan for, even in otherwise uncertain times. And thanks to its pricing power, the challenges surrounding inflation, electrification and autonomous driving are easy to master. As a result, Porsche is a highly attractive opportunity to be part of the luxury car segment. Morgan Stanley is more pessimistic. Porsche is a mixture of carmaker and luxury group, they said. But the impending recession would also put Porsche's business model to the test. Therefore, the analysts give the stock an "Equal Weight" with a price target of EUR 82.50. The sports car manufacturer's share is currently trading at around EUR 100. New price momentum could come with the possible promotion to the DAX.


    BioNTech is still on track: the cash box is bulging to drive the development pipeline forward. While the COVID-19 vaccine is yielding less profit, the business is far from dead. Pathfinder Ventures is an interesting exotic. Management shows that they are not only growing through acquisitions but also by developing existing sites. At Porsche, there is a current lack of impetus for further share price increases.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 24th, 2022 | 13:01 CET

    dynaCERT, Pathfinder Ventures, SFC Energy - Small caps on the upswing

    • Camping
    • greenhydrogen
    • Energy

    After the sharp corrections of the last months, the time of suffering of many shareholders of growth companies seems to be over. The companies, which have been badly affected by the stricter monetary policy, are sending clear signs of life, both in terms of charts and fundamentals. Volatility is likely to remain in the coming months. From a long-term perspective, however, there are attractive entry levels at a significantly cheaper level with opportunities for a strong rebound.

    Read